Barnaby Balmforth

Barnaby Balmforth

Chief Executive Officer

Barnaby has more than 10 years’ experience in the leadership of genomic technology development. Prior to co-founding Biofidelity he was Chief Operating Officer and Board member at Base4 as well as leading the development of the company’s molecular biology. Barnaby holds a PhD from the University of Cambridge and a Masters from the University of Oxford.

Stephen Miller

Stephen Miller

Chief Commercial Officer

Stephen has more than 25 years’ experience in the leadership of high growth public and private diagnostics businesses in the US, including at Precipio Inc., BG Medicine, Thermo Fisher Scientific and Athena Diagnostics. He has a track record of successful commercialisation of novel diagnostic technologies as well securing high-multiple transactions.

Wendy J. Levin

Wendy J. Levin

Chief Medical Officer

Dr Levin is a US-trained oncologist and haematologist with over 15 years’ industry experience in translational medicine and drug development, leading clinical development and medical affairs as well as supporting business development. She has provided strategic support for pre-IPO start-ups and Fortune 500 companies, led health authority and regulatory interactions, executed clinical advisory boards, provided clinical leadership for first-in-human studies to Phase 3 registration trials.

Robert Osborne

Robert Osborne

Chief Operating Officer

Robert has more than 15 years’ experience in the development and productization of genomic technologies, including more than a decade in product development at high growth start-ups. As SVP of Technology & Assay Development at Inivata he led flagship product development, from concept to CLIA/CAP-ready in less than 12 months, as well as the implementation ISO standards and design control in line with FDA requirements.

Magdalena Stolarek-Januszkiewicz

Magdalena Stolarek-Januszkiewicz

Head of R&D

Magdalena has a long background in the invention and development of novel genomic and molecular technologies from concept to the successful demonstration of world-leading capabilities. She holds a PhD in Plant Genetics and a Masters in Computer Science, and as Head of R&D leads the laboratory team as well as the advancement of the company’s core technology.

Heiner Dreismann

Heiner Dreismann

Chairman

A veteran executive with over 35 years’ experience in high growth life science and healthcare businesses, Dr Dreismann was a pioneer in the early adoption of PCR technologies. Formerly President & CEO of Roche Molecular Systems, he now serves on the boards of multiple healthcare companies in the US, Europe and Israel.

Barnaby Balmforth

Barnaby Balmforth

Chief Executive Officer

Barnaby has more than 10 years’ experience in the leadership of genomic technology development. Prior to co-founding Biofidelity he was Chief Operating Officer and Board member at Base4 as well as leading the development of the company’s molecular biology. Barnaby holds a PhD from the University of Cambridge and a Masters from the University of Oxford.

Cameron Frayling

Cameron Frayling

Co-Founder

The founder of multiple life science businesses, Cameron has more than 12 years’ experience in the development of genomics technologies and the growth of early-stage companies. He has developed an extensive industry network and established multiple life science collaborations. He is both co-founder of Biofidelity and co-inventor of the company’s underlying technology.

Ciarán O’Leary

Ciarán O’Leary

Director

Ciarán is a co-founder and General Partner at BlueYard Capital, a venture firm focusing on the decentralization of markets and the empowerment of humanity. Prior to co-founding BlueYard, Ciarán was a partner at VC firm Earlybird and before this was with the PE firm The Carlyle Group and M&A house Lazard.

Matthew Frohn

Matthew Frohn

Director

As a Partner at Longwall Ventures, Matthew predominantly focuses on life science opportunities. He holds a D.Phil in Biochemistry from the University of Oxford and has pre-venture experience ranging from working in clinical pathology to virology with Zeneca to drug development with Neures.